Get the Stockscreener App
0.3376
10.02%
-0.0376
Pre-market:
.32
-0.0176
-5.21%
Atyr Pharma Inc stock is traded at $0.3376, with a volume of 128.90M.
It is down -10.02% in the last 24 hours and down -36.30% over the past month.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
See More
Previous Close:
$0.3752
Open:
$0.4043
24h Volume:
128.90M
Relative Volume:
40.34
Market Cap:
$33.11M
Revenue:
$190.00K
Net Income/Loss:
$-70.03M
P/E Ratio:
-0.4598
EPS:
-0.7343
Net Cash Flow:
$-59.30M
1W Performance:
-10.33%
1M Performance:
-36.30%
6M Performance:
-57.24%
1Y Performance:
-64.50%
1-Day Range:
$0.324
$0.4074
1-Week Range:
$0.324
$0.4074
52-Week Range:
$0.324
$1.12
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.3376 | 33.11M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
$aTyr Pharma (ATYR.US)$ - moomoo.com
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease - AOL.com
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis - Yahoo Finance
aTyr Pharma Aligns with FDA on Efzofitimod Phase 3 - TipRanks
aTyr Pharma (NASDAQ: ATYR) Initiates Phase 3 Efzofitimod Trial with 5.0 mg/kg Dosing for Pulmonary Sarcoidosis - Kalkine Media
Why is aTyr Pharma stock surging today? By Investing.com - Investing.com Canada
Why is aTyr Pharma stock rallying today? By Investing.com - Investing.com Canada
Top Premarket Gainers - marketscreener.com
aTyr Pharma reports FDA alignment on sarcoidosis Phase 3 - Mugglehead Investment Magazine
aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial By Investing.com - Investing.com Canada
$aTyr Pharma (ATYR.US)$ 😘 looking for a nice entry again - Moomoo
aTyr Pharma reaches FDA alignment on phase 3 sarcoidosis trial - Investing.com
aTyr Pharma Announces FDA Alignment on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - Quiver Quantitative
aTyr Pharma Announces Alignment With FDA On Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis - TradingView
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewswire
ATyr Pharma, Inc.(NasdaqCM: ATYR) dropped from S&P Global BMI Index - marketscreener.com
aTyr Pharma (NASDAQ: ATYR) Schedules October 16 Vote on Reverse Stock Split Between 1-for-10 and 1-for-50 - Kalkine Media
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight - Yahoo Finance
aTyr Pharma (ATYR) Holds at $0.50 as Mild Buying Interest Supports Biotech Micro-CapThrowback Trade - siam.in
aTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis Study - Quiver Quantitative
Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis - TradingView
aTyr Pharma Provides Update on Timing of Regulatory - GlobeNewswire
FDA response expected by mid-September for aTyr’s lung disease trial - Stock Titan
aTyr Pharma Inc. (LIFE) Peer Comparison – Compare with Others - Value Research
Corporate Presentation Materials of aTyr Pharma, Inc. dated June 2026SEC.gov - SEC.gov
aTyr Pharma Inc. (LIFE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
aTyr (ATYR) Financial Results: Profit Per Share Surpasses Its Benchmark in the Latest Reading; The Stock Ends Down 0.20% in the Latest SessionSegment Revenue Breakdown - dars.gov.et
aTyr (ATYR) Snapshot: Falls 0.20% to $0.50 on the Day; Immediate View: Price Remains Between $0.47 Support and $0.53 Resistance in the Latest SessionPrice Momentum Stocks - vinanet.vn
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III - Freedom Broker
aTyr Pharma Company Profile & Introduction - Moomoo
ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesFree Cash Flow Trends - vinanet.vn
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - moomoo.com
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com India
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - moomoo.com
Why is aTyr Pharma stock gaining today? - Investing.com
Levi & Korsinsky Urges aTyr (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - The National Law Review
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ATyr Pharma Announces Second Quarter 2026 Res - Moomoo
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD - The Manila Times
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates - scanx.trade
ATYR Looks 13.6% Overvalued on GF Value™ as Cash Supports Develo - GuruFocus
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus - GuruFocus
ATyr Pharma Sees Funding Sufficient Into Late 2028 >ATYR - moomoo.com
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky - The National Law Review
ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - marketscreener.com
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Moomoo
Atyr Pharma Inc Stock (ATYR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):